Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01201785 · ClinicalTrials.gov registry record · Phase 4

Aspirin Dosing in Diabetic Patients

A Phase 4 study, sponsored by University of Florida.

Completed
Registry status
Phase 4
Development phase
20
Enrollment target

NCT01201785: Completed Phase 4 study, sponsored by University of Florida.

NCT01201785 is a Phase 4 study that has completed, run by University of Florida. The registered enrollment target is 20 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower). According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01201785, a Phase 4 study, has completed, sponsored by University of Florida.

COMPLETED
Registry status
Phase 4
Development phase
20 participants
Enrollment target

Study Summary

Since diabetic platelets are characterized by an enhanced turnover rate, it may be hypothesized that an increase in the frequency, rather than the dose, of drug administration may be a more effective strategy to inhibit platelet reactivity in diabetic patients as this may enable COX-1 blockade of newly generated platelets. However, how different dosing regimens impact the pharmacodynamic effects of aspirin selectively in diabetes mellitus has been poorly explored. Therefore, the aim of the present pilot investigation was to evaluate how increasing the frequency of aspirin administration, remaining within the daily recommended therapeutic doses, affects antiplatelet responsiveness in diabetic patients with coronary artery disease.

Primary Outcome

Collagen induced aggregation using light transmittance aggregometry

Interventions

  • DRUG Aspirin

Trial Details

FieldValue
Enrollment Target 20 participants
Start Date 2009-01
Est. Completion 2010-09
Phase Phase 4
University of Florida

1,106 total trials

What the finished NCT01201785 record still lists

NCT01201785 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (96% lower).

The record links to 0 conditions, and to 1 intervention - of which Aspirin is the first listed.

NCT01201785 does not publish any study locations in the registry export this page uses.

Frequently Asked Questions

What is clinical trial NCT01201785 about?

NCT01201785 is a clinical study titled "Aspirin Dosing in Diabetic Patients". Since diabetic platelets are characterized by an enhanced turnover rate, it may be hypothesized that an increase in the frequency, rather than the dose, of drug administration may be a more effective strategy to inhibit platelet reactivity in diabetic patients as this may enable COX-1 blockade of ne...

What is the current status of trial NCT01201785?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2009-01. Estimated completion is 2010-09.

What interventions are being tested in trial NCT01201785?

The interventions under investigation include: Aspirin (DRUG).

Who is sponsoring clinical trial NCT01201785?

This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.

How this trial's enrollment target compares

Where NCT01201785's enrollment target sits among peer trials

20 1753rd of 2000 higher than 167 of 2,000 other Phase 4 trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT00573339 · 20 participants

    Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing

  • NCT00692939 · 20 participants · Phase 1

    Autologous Stem Cell Transplantation for Crohn's Disease

  • NCT00967785 · 20 participants · Phase 1

    A Phase I Study of Mozobil in the Treatment of Patients With WHIMS

  • NCT01406691 · 20 participants · Phase 4

    Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01201785, the US trial registry maintained by the National Library of Medicine. NCT01201785 (small enrollment · none site footprint · completed) retrieved and formatted by PlainTrial, see methodology.